journal article·2015-06Open access

Co-delivery of paclitaxel and gemcitabine via CD44-targeting nanocarriers as a prodrug with synergistic antitumor activity against human biliary cancer

Ilkoo Noh, Hyun-Ouk Kim, Jihye Choi, Yuna Choi, Dong Ki Lee, Yong-Min Huh, Seungjoo Haam

Biomaterials· Volume 53

Abstract

Multi-drug delivery focuses on different signaling pathways in cancer cells that have synergistic anti-proliferative effects. In this study, we developed multi-prodrug nanocarriers (MPDNCs) consisting of poly (l-lysine)-carboxylate PTX (PLL-PTX) and hyaluronic acid-conjugated GEM (HA-GEM) for CD44-targeted synergistic biliary cancer therapy. An in vitro study of cell viability and mRNA expression levels and an in vivo study showed that MPDNCs more effectively inhibit proliferation in CD44-overexpressing cancer cells (HuCCT1) than in cells with lower CD44 expression (SCK) by synergistically inducing apoptosis. Consequently, these results demonstrate that MPDNCs are prodrugs with synergistic cancer therapeutic efficacy and effective cellular uptake at target cells compared to free drugs, indicating their strong potential as efficient multi-drug-carrying nano-platforms for cancer treatment.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Cholangiocarcinoma and Gallbladder Cancer Studies · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (52)

Show source-provided references
1. Combination cancer therapy: presidential address
2. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment10.1200/JCO.2007.11.9362 ↗
3. Combinational delivery of hydrophobic and hydrophilic anticancer drugs in single nanoemulsions to treat MDR in cancer10.1021/mp400778r ↗
4. Simultaneous delivery of siRNA and paclitaxel via a “two-in-one” micelleplex promotes synergistic tumor suppression10.1021/nn103349h ↗
5. Engineering particles for therapeutic delivery: prospects and challenges10.1021/nn3016162 ↗
6. Gene and doxorubicin co-delivery system for targeting therapy of glioma10.1016/j.biomaterials.2012.03.031 ↗
7. Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram10.1021/nn4010796 ↗
8. Hydrotropic solubilization of paclitaxel: analysis of chemical structures for hydrotropic property10.1023/A:1024458206032 ↗
9. Strategies for the nanoencapsulation of hydrophilic molecules in polymer-based nanoparticles10.1016/j.biomaterials.2011.07.057 ↗
10. Cancer multidrug resistance10.1038/5289 ↗
11. Multifunctional nanogels for siRNA delivery10.1021/ar200216f ↗
12. Vitamin E TPGS prodrug micelles for hydrophilic drug delivery with neuroprotective effects10.1016/j.ijpharm.2012.08.038 ↗
13. Targeted co-delivery of docetaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment of cancer10.1016/j.jconrel.2013.01.035 ↗
14. siRNA-based nanomedicine10.2217/nnm.13.73 ↗
15. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer10.1016/j.bcp.2012.01.008 ↗
16. Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs10.1016/j.jconrel.2009.04.024 ↗
17. Liposomes as sterile preparations and limitations of sterilisation techniques in liposomal manufacturing
18. Preparation and characterization of nanoparticles formed by chitosan-caseinate interactions10.1016/j.colsurfb.2008.01.010 ↗
19. Polymer-drug conjugates: progress in polymeric prodrugs10.1016/j.progpolymsci.2005.09.004 ↗
20. Poly-cyclodextrin and poly-paclitaxel nano-assembly for anticancer therapy10.1038/ncomms4702 ↗
21. Therapeutic nanoparticles for drug delivery in cancer10.1158/1078-0432.CCR-07-1441 ↗
22. Nanoparticles for combination drug therapy10.1021/nn405674m ↗
23. Lactoferrin-conjugated biodegradable polymersome holding doxorubicin and tetrandrine for chemotherapy of glioma rats10.1021/mp100277h ↗
24. Targeted therapy for cancer
25. Cholangiocarcinoma10.1016/S0140-6736(05)67530-7 ↗
26. Ursodeoxycholic acid-conjugated chitosan for photodynamic treatment of HuCC-T1 human cholangiocarcinoma cells10.1016/j.ijpharm.2013.06.035 ↗
27. Aberrant expression of CD44 in bile duct cancer correlates with poor prognosis
28. Silencing of CD44 by siRNA suppressed invasion, migration and adhesion to matrix, but not secretion of MMPs, of cholangiocarcinoma cells10.1007/s10585-011-9414-8 ↗
29. The biological significance of hyaluronic acid and hyaluronidase10.1152/physrev.1947.27.3.335 ↗
30. Preclinical characteristics of gemcitabine10.1097/00001813-199512006-00002 ↗
31. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol10.1093/jnci/83.4.288 ↗
32. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial10.1200/JCO.2002.11.050 ↗
33. Establishment of a controlled insulin delivery system using a glucose-responsive double-layered nanogel10.1039/C4RA16656F ↗
34. Combinatorial drug conjugation enables nanoparticle dual-drug delivery10.1002/smll.201000631 ↗
35. A biodegradable polymersome containing Bcl-xL siRNA and doxorubicin as a dual delivery vehicle for a synergistic anticancer effect10.1002/mabi.201200448 ↗
36. Highly selective CD44-specific gold nanorods for photothermal ablation of tumorigenic subpopulations generated in MCF7 mammospheres10.1088/0957-4484/23/46/465101 ↗
37. Tumor targeting and pH-responsive polyelectrolyte complex nanoparticles based on hyaluronic acid-paclitaxel conjugates and chitosan for oral delivery of paclitaxel10.1007/s13233-013-1171-x ↗
38. π-Hyaluronan nanocarriers for CD44-targeted and pH-boosted aromatic drug delivery10.1039/c3tb20906g ↗
39. Aptamer-conjugated gold nanorod for photothermal ablation of epidermal growth factor receptor-overexpressed epithelial cancer10.1117/1.JBO.19.5.051203 ↗
40. Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes10.1083/jcb.97.2.329 ↗
41. A biodegradable polymersome with pH-tuning on-off membrane based on poly(beta-amino ester) for drug delivery10.1002/mabi.201200468 ↗
42. Design, synthesis and applications of hyaluronic acid-paclitaxel bioconjugates10.3390/molecules13020360 ↗
43. Folate-mediated targeting of polymeric conjugates of gemcitabine10.1016/j.ijpharm.2005.10.015 ↗
44. Amino acid grafted chitosan for high performance gene delivery: comparison of amino acid hydrophobicity on vector and polyplex characteristics10.1021/bm301720g ↗
45. Hyaluronan-modified magnetic nanoclusters for detection of CD44-overexpressing breast cancer by MR imaging10.1016/j.biomaterials.2011.06.077 ↗
46. Combinatorial evaluation of cations, pH-sensitive and hydrophobic moieties for polymeric vector design10.1038/mt.2008.293 ↗
47. The role of hydrophobic alkyl chains in the physicochemical properties of poly(beta-amino ester)/DNA complexes10.1016/j.colsurfb.2014.11.048 ↗
48. Crystal and molecular structure of paclitaxel (taxol)10.1073/pnas.92.15.6920 ↗
49. Effect of pH on the behavior of hyaluronic acid in dilute and semidilute aqueous solutions10.1002/masy.200851418 ↗
50. Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis10.4161/cbt.5.8.2909 ↗
51. Apoptosis and apoptosis-related factors Bcl-2, Bax, tumor necrosis factor-α, and NF-κB in human endometrial hyperplasia and carcinoma10.1002/cncr.10876 ↗
52. Targetable gold nanorods for epithelial cancer therapy guided by near-IR absorption imaging10.1002/smll.201101789 ↗